Predictive biomarkers of bacillus Calmette-Guérin immunotherapy response in bladder cancer: Where are we now?

Advances in Urology

Volumn , Issue , 2012, Pages

  Lima, Luís ^a,b,c   Dinis Ribeiro, Mário ^a,d   Longatto Filho, Adhemar ^e,f,g   Santos, Lúcio ^a,h  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^d University of Porto   (Portugal)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF MINHO   (Portugal)

^g BARRETOS CANCER HOSPITAL   (Brazil)

^h UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866253149     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2012/232609     Document Type: Review

References (104)

1. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Böhle A., Palou-Redorta J., Rouprêt M., EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. European Urology 2011 59 6 997 1008 2-s2.0-79955593955 10.1016/j.eururo.2011.03.017
2. Han R. F., Pan J. G., Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006 67 6 1216 1223 2-s2.0-33744513525 10.1016/j.urology.2005.12.014 (Pubitemid 43818066)
3. Shelley M. D., Kynaston H., Court J., Wilt T. J., Coles B., Burgon K., Mason M. D., A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. British Journal of Urology International 2001 88 3 209 216 2-s2.0-0034819965 10.1046/j.1464-410X.2001.02306.x (Pubitemid 32863039)
4. Sylvester R. J., Van der Meijden A. P. M., Lamm D. L., Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. Journal of Urology 2002 168 5 1964 1970 2-s2.0-0036837453
5. Brake M., Loertzer H., Horsch R., Keller H., Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. Journal of Urology 2000 163 6 1697 1701 2-s2.0-0034096908 (Pubitemid 30366716)
6. Brake M., Loertzer H., Horsch R., Keller H., Long-term results of intravesical bacillus calmette-guérin therapy for stage T1 superficial bladder cancer. Urology 2000 55 5 673 678 2-s2.0-0034184840
7. Fernandez-Gomez J., Solsona E., Unda M., Martinez-Piñeiro L., Gonzalez M., Hernandez R., Madero R., Ojea A., Pertusa C., Rodriguez-Molina J., Camacho J. E., Isorna S., Rabadan M., Astobieta A., Montesinos M., Muntañola P., Gimeno A., Blas M., Martinez-Piñeiro J. A., Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. European Urology 2008 53 5 992 1002 2-s2.0-41149144274 10.1016/j.eururo.2007.10.006 (Pubitemid 351434495)
8. Lamm D. L., Bacillus Calmette-Guerin immunotherapy for bladder cancer. Journal of Urology 1985 134 1 40 47 2-s2.0-0021843932 (Pubitemid 15006784)
9. Peyromaure M., Guerin F., Amsellem-Ouazana D., Saighi D., Debre B., Zerbib M., Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. Journal of Urology 2003 169 6 2110 2112 2-s2.0-0037950142 10.1097/01.ju.0000066840.42991.4a (Pubitemid 36576728)
10. Kresowik T. P., Griffith T. S., Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy 2009 1 2 281 288 2-s2.0-77953375599 10.2217/1750743X.1.2.281
11. Lamm D. L., Van der Meijden A. P. M., Morales A., Brosman S. A., Catalona W. J., Herr H. W., Soloway M. S., Steg A., Debruyne F. M. J., Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. Journal of Urology 1992 147 3 I 596 600 2-s2.0-0026578493
12. Böhle A., Jocham D., Bock P. R., Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. Journal of Urology 2003 169 1 90 95 2-s2.0-0037213844 (Pubitemid 35461559)
13. Lamm D. L., Blumenstein B. A., Crissman J. D., Montie J. E., Gottesman J. E., Lowe B. A., Sarosdy M. F., Bohl R. D., Grossman H. B., Beck T. M., Leimert J. T., Crawford E. D., Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. Journal of Urology 2000 163 4 1124 1129 2-s2.0-0034105381 (Pubitemid 30169376)
14. Van der Meijden A. P. M., Sylvester R. J., Oosterlinck W., Hoeltl W., Bono A. V., Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial. European Urology 2003 44 4 429 434 2-s2.0-0141460505 10.1016/S0302-2838(03)00357-9 (Pubitemid 37185667)
15. Schrohl A. S., Holten-Andersen M., Sweep F., Schmitt M., Harbeck N., Foekens J., Brünner N., Tumor markers: from laboratory to clinical utility. Molecular & Cellular Proteomics 2003 2 6 378 387 2-s2.0-2542612580
16. Alexandroff A. B., Nicholson S., Patel P. M., Jackson A. M., Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy 2010 2 4 551 560 2-s2.0-77954980492 10.2217/imt.10.32
17. von Elm E., Altman D. G., Egger M., Pocock S. J., Gotzsche P. C., Vandenbroucke J. P., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Journal of Clinical Epidemiology 2008 61 4 344 349 2-s2.0-39649090053 10.1016/j.jclinepi.2007.11.008 (Pubitemid 351289042)
18. Lacombe L., Dalbagni G., Zhang Z. F., Cordon-Cardo C., Fair W. R., Herr H. W., Reuter V. E., Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after Bacillus Calmette-Guerin therapy: correlation to clinical outcome. Journal of Clinical Oncology 1996 14 10 2646 2652 2-s2.0-0029768723 (Pubitemid 26329648)
19. Caliskan M., Türkeri L. N., Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer. British Journal of Urology 1997 79 3 373 377 2-s2.0-0031400827 (Pubitemid 28318974)
20. Okamura T., Akita H., Kawai N., Tozawa K., Yamada Y., Kohri K., Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 expression during bacillus calmette-guerin (BCG) intravesical instillation therapy for superficial bladder cancers. Urological Research 1998 26 3 161 164 2-s2.0-0031747149 10.1007/s002400050040 (Pubitemid 28305379)
21. Lebret T., Becette V., Barbagelatta M., Hervé J. M., Gaudez F., Barré P., Lugagne P. M., Botto H., Correlation between p53 over expression and response to bacillus calmette-guerin therapy in a high risk select population of patients with T1G3 bladder cancer. Journal of Urology 1998 159 3 788 791 2-s2.0-0031950890 10.1016/S0022-5347(01)63731-5 (Pubitemid 28106526)
22. Zlotta A. R., Noel J. C., Fayt I., Drowart A., Van Vooren J. P., Huygen K., Simon J., Schulman C. C., Correlation and prognostic significance of p53, p21(WAF1/CIP1) and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. Journal of Urology 1999 161 3 792 798 2-s2.0-0032877579 10.1016/S0022-5347(01)61770-1 (Pubitemid 29422368)
23. Saint F., Le Frere Belda M. A., Quintela R., Hoznek A., Patard J. J., Bellot J., Popov Z., Zafrani E. S., Abbou C. C., Chopin D. K., De Medina S. G. D., Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG). European Urology 2004 45 4 475 482 2-s2.0-12144288735 10.1016/j.eururo.2003.11. 018 (Pubitemid 38376210)
24. Peyromaure M., Weibing S., Sebe P., Verpillat P., Toublanc M., Dauge M. C., Boccon-Gibod L., Ravery V., Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy. Urology 2002 59 3 409 413 2-s2.0-0036184642 10.1016/S0090-4295(01)01551-5 (Pubitemid 34189744)
25. Pages F., Flam T. A., Vieillefond A., Molinie V., Abeille X., Lazar V., Bressac-de Paillerets B., Mosseri V., Zerbib M., Fridman W. H., Debré B., Thiounn N., p53 status does not predict initial clinical response to bacillus calmette-guerin intravesical therapy in T1 bladder tumors. Journal of Urology 1998 159 3 1079 1084 2-s2.0-0031932476 10.1016/S0022-5347(01)63839-4 (Pubitemid 28106597)
26. Park J., Song C., Shin E., Hong J. H., Kim C. S., Ahn H., Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urologic Oncology 2011 2-s2.0-79960347723 10.1016/j.urolonc.2011.06.004
27. Kyroudi-Voulgari A., Kouloukoussa M., Simigiatos C., Karakitsos P., Zervas A., Kittas C., Mitropoulos D., DNA ploidy and immunomarking of bladder urothelial tumors before and after intravesical bacillus Calmette-Guérin treatment. Analytical and Quantitative Cytology and Histology 2005 27 1 52 60 2-s2.0-14344253602 (Pubitemid 40293592)
28. Serdar A., Turhan C., Soner G., Cem S. N., Bayram K., Damla B. E., Erbil E., The prognostic importance of e-cadherin and p53 gene expression in transitional bladder carcinoma patients. International Urology and Nephrology 2005 37 3 485 492 2-s2.0-28844448630 10.1007/s11255-005-0919-4 (Pubitemid 41762502)
29. Moyano Calvo J. L., Blanco Palenciano E., Beato Moreno A., Gutiérrez González M., Pérez-Lanzac Lorca A., Samaniego Torres A., Montaño J. A., Castiñeiras Fernández J., Prognostic value of E-Cadherina, Beta Catenin, KI, Ki-67 antigen and p53 protein in the superficial bladder tumors. Actas Urologicas Espanolas 2006 30 9 871 878 2-s2.0-34347209111
30. Esuvaranathan K., Chiong E., Thamboo T. P., Chan Y. H., Kamaraj R., Mahendran R., Teh M., Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 2007 109 6 1097 1105 2-s2.0-33947209498 10.1002/cncr.22503 (Pubitemid 46435388)
31. Palou J., Algaba F., Vera I., Rodriguez O., Villavicencio H., Sanchez-Carbayo M., Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance Bacillus Calmette-Guérin. European Urology 2009 56 5 829 836 2-s2.0-70349268329 10.1016/j.eururo.2008.09.062
32. Cormio L., Tolve I., Annese P., Saracino A., Zamparese R., Sanguedolce F., Bufo P., Battaglia M., Selvaggi F. P., Carrieri G., Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Research 2009 29 10 4201 4204 2-s2.0-71949095084
33. Moyano Calvo J. L., De Miguel Rodríguez M., Poyato Galán J. M., Ortíz Gamiz A., Molina Carranza A., Zerpa Railey J. J., Toro Cepeda H., Sánchez-Barriga Peña D., Galera Davidson H., Castiñeiras Fernández J., Flow cytometry, DNA ploidy, Ki-67 label and overexpression of p53 protein in 121 T1 superficial bladder cancer. Retrospective study. 2nd Part: prognostic value and utility in the selection of the tretment with prophylactic BCG. Actas Urologicas Espanolas 2001 25 1 32 45 2-s2.0-0035105752 (Pubitemid 32199913)
34. Lopez-Beltran A., Luque R. J., Alvarez-Kindelan J., Quintero A., Merlo F., Carrasco J. C., Requena M. J., Montironi R., Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). European Urology 2004 45 5 606 612 2-s2.0-1842737599 10.1016/j.eururo.2003.11.011 (Pubitemid 38481688)
35. Lee E., Park I., Lee C., Prognostic markers of intravesical bacillus Calmette-Guerin therapy for multiple, high-grade, stage T1 bladder cancers. International Journal of Urology 1997 4 6 552 556 2-s2.0-0031452490 (Pubitemid 28021292)
36. Pfister C., Flaman J. M., Dunet F., Grise P., Frebourg T., p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy. Journal of Urology 1999 162 1 69 73 2-s2.0-0032825985 10.1097/00005392-199907000-00017 (Pubitemid 29420882)
37. Lebret T., Becette V., Hervé J. M., Molinié V., Barré P., Lugagne P. M., Gentille A., Baglin A. C., Botto H., Prognostic value of MIB-1 antibody labeling index to predict response to bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. European Urology 2000 37 6 654 659 2-s2.0-0034099965 (Pubitemid 30255780)
38. Blanchet P., Droupy S., Eschwege P., Viellefond A., Paradis V., Pichon M. F., Jardin A., Benoit G., Prospective evaluation of Ki-67 labeling in predicting the recurrence and progression of superficial bladder transitional cell carcinoma. European Urology 2001 40 2 169 175 2-s2.0-0034864878 10.1159/000049768 (Pubitemid 32786103)
39. Cormio L., Tolve I., Annese P., Saracino A., Zamparese R., Sanguedolce F., Bufo P., Battaglia M., Selvaggi F. P., Carrieri G., Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer. Urologic Oncology 2010 28 3 285 289 2-s2.0-77951572370 10.1016/j.urolonc.2008.08.003
40. Mantovani A., Germano G., Marchesi F., Locatelli M., Biswas S. K., Cancer-promoting tumor-associated macrophages: new vistas and open questions. European Journal of Immunology 2011 41 9 2522 2525 2-s2.0-80052138920 10.1002/eji.201141894
41. Ayari C., LaRue H., Hovington H., Decobert M., Harel F., Bergeron A., Têtu B., Lacombe L., Fradet Y., Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to Bacillus Calmette-Guérin immunotherapy. European Urology 2009 55 6 1386 1396 2-s2.0-65049091771 10.1016/j.eururo.2009.01.040
42. Takayama H., Nishimura K., Tsujimura A., Nakai Y., Nakayama M., Aozasa K., Okuyama A., Nonomura N., Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. Journal of Urology 2009 181 4 1894 1900 2-s2.0-61949486981 10.1016/j.juro.2008.11.090
43. Janane A., Hajji F., Ismail T. O., Elondo J. C., Ghadouane M., Ameur A., Abbar M., Bouzidi A., Evaluation of HER2 protein overexpression in non-muscle invasive bladder cancer with emphasis on tumour grade and recurrence. Actas Urologicas Espanolas 2011 35 4 189 194 2-s2.0-79953328483 10.1016/j.acuro.2010. 11.017
44. Lopez-Beltran A., Ordóñez J. L., Otero A. P., Blanca A., Sevillano V., Sanchez-Carbayo M., Muñoz E., Cheng L., Montironi R., De Alava E., Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Archiv 2010 457 5 555 561 2-s2.0-78149469992 10.1007/s00428-010-0969-6
45. Kim S. I. L., Kwon S. M., Kim Y. S., Hong S. J., Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 2002 60 5 816 821 2-s2.0-0036844775 10.1016/S0090-4295(02)01909-X (Pubitemid 35300345)
46. Yutkin V., Pode D., Pikarsky E., Mandelboim O., The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study. Journal of Urology 2007 178 6 2660 2664 2-s2.0-35748940270 10.1016/j.juro.2007.07.118 (Pubitemid 350052144)
47. Lebret T., Watson R. W. G., Molinié V., Poulain J. E., O'Neill A., Fitzpatrick J. M., Botto H., HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours. European Urology 2007 51 1 161 167 2-s2.0-33751398435 10.1016/j.eururo.2006.06.006 (Pubitemid 44821520)
48. Kitamura H., Torigoe T., Honma I., Sato E., Asanuma H., Hirohashi Y., Sato N., Tsukamoto T., Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of Bacillus Calmette-Guerin immunotherapy for bladder cancer. Clinical Cancer Research 2006 12 15 4641 4644 2-s2.0-33748070506 10.1158/1078-0432.CCR-06-0595 (Pubitemid 44297816)
49. Gazzaniga P., Gradilone A., De Berardinis E., Sciarra A., Cristini C., Naso G., Di Silverio F., Frati L., Aglianò A. M., A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer. British Journal of Urology International 2009 104 2 184 188 2-s2.0-67650647141 10.1111/j.1464-410X.2008.08342.x
50. Videira P. A., Calais F. M., Correia M., Ligeiro D., Crespo H. J., Calais F., Trindade H., Efficacy of bacille Calmette-Guerin immunotherapy predicted by expression of antigen-presenting molecules and chemokines. Urology 2009 74 4 944 950 2-s2.0-70349448333 10.1016/j.urology.2009.02.053
51. Kim Y. J., Ha Y. S., Kim S. K., Yoon H., Lym M. S., Kim M. J., Moon S. K., Choi Y. H., Kim W. J., Gene signatures for the prediction of response to Bacillus Calmette-Guérin immunotherapy in primary pT1 bladder cancers. Clinical Cancer Research 2010 16 7 2131 2137 2-s2.0-77950685757 10.1158/1078-0432.CCR-09-3323
52. Alvarez-Múgica M., Cebrian V., Fernández-Gómez J. M., Fresno F., Escaf S., Sánchez-Carbayo M., Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer. Journal of Urology 2010 184 4 1507 1513 2-s2.0-77955548455 10.1016/j.juro.2010.05.085
53. Agundez M., Grau L., Palou J., Algaba F., Villavicencio H., Sanchez-Carbayo M., Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. European Urology 2011 60 1 131 140 2-s2.0-79957954273 10.1016/j.eururo.2011.04.020
54. Sagnak L., Ersoy H., Ozok U., Senturk B., Ercil H., Bahar G., Ozturk E., Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus calmette-guérin treatment in non-muscle-invasive bladder tumors. Clinical Genitourinary Cancer 2009 7 2 E16 E23 2-s2.0-70449378659 10.3816/CGC.2009.n.016
55. Shintani Y., Sawada Y., Inagaki T., Kohjimoto Y., Uekado Y., Shinka T., Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy. International Journal of Urology 2007 14 2 140 146 2-s2.0-33846324801 10.1111/j.1442-2042.2007.01696.x (Pubitemid 46121952)
56. Watanabe E., Matsuyama H., Matsuda K., Ohmi C., Tei Y., Yoshihiro S., Ohmoto Y., Naito K., Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. Cancer Immunology, Immunotherapy 2003 52 8 481 486 2-s2.0-0041903671 10.1007/s00262-003-0384-9 (Pubitemid 36963209)
57. Kumar A., Dubey D., Bansal P., Mandhani A., Naik S., Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus calmette-guerin (modified Danish 1331 strain) for superficial bladder cancer. Journal of Urology 2002 168 5 2232 2235 2-s2.0-0036837255
58. Sánchez-Carbayo M., Urrutia M., Romani R., Herrero M., Gonzalez De Buitrago J. M., Navajo J. A., Serial urinary IL-2, IL-6, IL-8, TNF α UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG. Anticancer Research 2001 21 4 B 3041 3047 2-s2.0-0035160605 (Pubitemid 33051173)
59. Thalmann G. N., Sermier A., Rentsch C., Möhrle K., Cecchini M. G., Studer U. E., Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. Journal of Urology 2000 164 6 2129 2133 2-s2.0-0033757837
60. Jackson A. M., Ivshina A. V., Senko O., Kuznetsova A., Sundan A., O'Donnell M. A., Clinton S., Alexandroff A. B., Selby P. J., James K., Kuznetsov V. A., Prognosis of intravesical bacillus calmette-guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndromes analysis. Journal of Urology 1998 159 3 1054 1063 2-s2.0-0031905978 10.1016/S0022-5347(01)63835-7 (Pubitemid 28106593)
61. Thalmann G. N., Dewald B., Baggiolini M., Studer U. E., Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. Journal of Urology 1997 158 4 1340 1344 2-s2.0-0030750959 10.1016/S0022-5347(01)64210-1 (Pubitemid 27391191)
62. Rabinowitz R., Smith D. S., Tiemann D. D., Hudson M. A., Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients. Journal of Urology 1997 158 5 1728 1732 2-s2.0-0030863591 10.1016/S0022-5347(01)64111-9 (Pubitemid 27433141)
63. Saint F., Kurth N., Maille P., Vordos D., Hoznek A., Soyeux P., Patard J. J., Abbou C. C., Chopin D. K., Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy. International Journal of Cancer 2003 107 3 434 440 2-s2.0-0142090687 10.1002/ijc.11352 (Pubitemid 37266464)
64. Saint F., Patard J. J., Maille P., Soyeux P., Hoznek A., Salomon L., Abbou C. C., Chopin D. K., Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. Journal of Urology 2002 167 1 364 367 2-s2.0-0036135232 (Pubitemid 34024586)
65. Saint F., Patard J. J., Maille P., Soyeux P., Hoznek A., Salomon L., De La Taille A., Abbou C. C., Chopin D. K., T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus calmette-guerin for superficial bladder cancer. Journal of Urology 2001 166 6 2142 2147 2-s2.0-0035170063 (Pubitemid 33065239)
66. De Reijke T. M., De Boer E. C., Kurth K. H., Schamhart D. H. J., Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. Journal of Urology 1996 155 2 477 482 2-s2.0-0030051368 10.1016/S0022-5347(01)66424-3 (Pubitemid 26023528)
67. Eto M., Koga H., Noma H., Yamaguchi A., Yoshikai Y., Naito S., Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus Calmette-Guérin for superficial bladder tumors. Urologia Internationalis 2005 75 2 114 118 2-s2.0-23944455343 10.1159/000087163 (Pubitemid 41208873)
68. Hausladen D. A., Wheeler M. A., Altieri D. C., Colberg J. W., Weiss R. M., Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome. Journal of Urology 2003 170 1 230 234 2-s2.0-0038002720 10.1097/01.ju. 0000063685.29339.24 (Pubitemid 36734468)
69. Danişman A., Bulut K., Kukul E., Özen I., Sevük M., Urinary fibronectin levels in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer. Urologia Internationalis 2000 64 4 198 201 2-s2.0-0343193310 (Pubitemid 30458958)
70. Kaempfer R., Gerez L., Farbstein H., Madar L., Hirschman O., Nussinovich R., Shapiro A., Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. Journal of Clinical Oncology 1996 14 6 1778 1786 2-s2.0-0029885357 (Pubitemid 26185455)
71. Magno C., Melloni D., Galì A., Mucciardi G., Nicocia G., Morandi B., Melioli G., Ferlazzo G., The anti-tumor activity of bacillus Calmette-Guerin in bladder cancer is associated with an increase in the circulating level of interleukin-2. Immunology Letters 2002 81 3 235 238 2-s2.0-0036569190 10.1016/S0165-2478(02)00040-8 (Pubitemid 34310231)
72. Bilen C. Y., Inci K., Erkan I., Özen H., The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin. Journal of Urology 2003 169 5 1702 1705 2-s2.0-0037404236 10.1097/01.ju.0000059681.67567.12 (Pubitemid 36443475)
73. Chiong E., Kesavan A., Mahendran R., Chan Y. H., Sng J. H., Lim Y. K., Kamaraj R., Tan T. M. C., Esuvaranathan K., NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guérin therapy for bladder cancer. European Urology 2011 59 3 430 437 2-s2.0-79551473161 10.1016/j.eururo.2010.11. 031
74. Decobert M., LaRue H., Bergeron A., Harel F., Pfister C., Rousseau F., Lacombe L., Fradet Y., Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. Journal of Urology 2006 175 4 1506 1511 2-s2.0-33644603499 10.1016/S0022-5347(05)00653-1
75. Gu J., Zhao H., Dinney C. P., Zhu Y., Leibovici D., Bermejo C. E., Grossman H. B., Wu X., Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clinical Cancer Research 2005 11 4 1408 1415 2-s2.0-14644437738 10.1158/1078-0432.CCR-04-1101 (Pubitemid 40315220)
76. Gangwar R., Mandhani A., Mittal R. D., XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. Journal of Cancer Research and Clinical Oncology 2010 136 5 779 786 2-s2.0-77950505332 10.1007/s00432-009-0717-y
77. Gangawar R., Ahirwar D., Mandhani A., Mittal R. D., Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India. Medical Oncology 2010 27 2 159 166 2-s2.0-77956920390 10.1007/s12032-009-9187-y
78. Mittal R. D., Singh R., Manchanda P. K., Ahirwar D., Gangwar R., Kesarwani P., Mandhani A., XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. Cancer Biology & Therapy 2008 7 5 645 650 2-s2.0-56149116930
79. Mittal R. D., Gangwar R., Mandal R. K., Srivastava P., Ahirwar D. K., Gene variants of XRCC4 and XRCC3 and their association with risk for urothelial bladder cancer. Molecular Biology Reports 2011 39 2 1667 1675 2-s2.0-80955175948 10.1007/s11033-011-0906-z
80. Ahirwar D. K., Agrahari A., Mandhani A., Mittal R. D., Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Biomarkers 2009 14 4 213 218 2-s2.0-68549123632 10.1080/13547500902818246
81. Ahirwar D. K., Mandhani A., Mittal R. D., IL-8 -251 T > A Polymorphism associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a northern Indian cohort. Archives of Medical Research 2010 41 2 97 103 2-s2.0-77952763231 10.1016/j.arcmed.2010.03.005
82. Cai T., Nesi G., Dal Canto M., Tinacci G., Mondaini N., Piazzini M., Geppetti P., Bartoletti R., Loss of heterozygosis on IFN-alpha locus is a prognostic indicator of bacillus Calmette-Guerin response for nonmuscle invasive bladder cancer. Journal of Urology 2010 183 5 1738 1743 2-s2.0-77950517366 10.1016/j.juro.2009.12.105
83. Gangwar R., Mandhani A., Mittal R. D., Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. Surgery 2011 149 1 126 134 2-s2.0-78650170738 10.1016/j.surg.2010.04.004
84. Ahirwar D., Kesarwani P., Manchanda P. K., Mandhani A., Mittal R. D., Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer. Cancer Genetics and Cytogenetics 2008 184 1 1 8 2-s2.0-44949186585 10.1016/j.cancergencyto.2008.02. 015 (Pubitemid 351814965)
85. Ahirwar D. K., Mandhani A., Dharaskar A., Kesarwani P., Mittal R. D., Association of tumour necrosis factor- α gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guérin immunotherapy. British Journal of Urology International 2009 104 6 867 873 2-s2.0-69249089344 10.1111/j.1464-410X.2009. 08549.x
86. Leibovici D., Grossman H. B., Dinney C. P., Millikan R. E., Lerner S., Wang Y., Gu J., Dong Q., Wu X., Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. Journal of Clinical Oncology 2005 23 24 5746 5756 2-s2.0-24944558497 10.1200/JCO.2005.01. 598
87. Baştürk B., Yavaşçaolu I., Vuruşkan H., Göral G., Oktay B., Oral H. B., Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. Cytokine 2005 30 1 41 45 2-s2.0-15244357265 10.1016/j.cyto.2004.10.016 (Pubitemid 40387354)
88. Gangwar R., Mandhani A., Mittal R. D., Caspase 9 and Caspase 8 gene polymorphisms and susceptibility to bladder cancer in North Indian population. Annals of Surgical Oncology 2009 16 7 2028 2034 2-s2.0-67649173095 10.1245/s10434-009-0488-3
89. Gangwar R., Mittal R. D., Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in north Indian population. DNA and Cell Biology 2010 29 7 349 356 2-s2.0-77954912151 10.1089/dna.2009.0982
90. Srivastava P., Gangwar R., Kapoor R., Mittal R. D., Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. Disease Markers 2010 29 1 37 46 2-s2.0-77957236220 10.3233/DMA-2010-0724
91. Srivastava P., Kapoor R., Mittal R. D., Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India. Urologic Oncology 2011 2-s2.0-79960540537 10.1016/j.urolonc.2011.01.001
92. Srivastava P., Mandhani A., Kapoor R., Mittal R. D., Role of MMP-3 and MMP-9 and their haplotypes in risk of bladder cancer in North Indian cohort. Annals of Surgical Oncology 2010 17 11 3068 3075 2-s2.0-78049459070 10.1245/s10434-010-1153-6
93. Chen M., Hildebrandt M. A. T., Clague J., Kamat A. M., Picornell A., Chang J., Zhang X., Izzo J., Yang H., Lin J., Gu J., Chanock S., Kogevinas M., Rothman N., Silverman D. T., Garcia-Closas M., Barton Grossman H., Dinney C. P., Malats N., Wu X., Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prevention Research 2010 3 10 1235 1245 2-s2.0-77958611363 10.1158/1940-6207.CAPR-10-0035
94. Zuiverloon T. C. M., Nieuweboer A. J. M., Vékony H., Kirkels W. J., Bangma C. H., Zwarthoff E. C., Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. European Urology 2012 61 1 128 145 2-s2.0-82255192477 10.1016/j.eururo.2011.09.026
95. Morgan B. E., Salup R., Morgan M. B., Differential C-erbB-2 and VEGF expression following BCG immunotherapy in superficial papillary transitional cell carcinoma of the bladder. Urologic Oncology 2002 7 2 67 72 2-s2.0-0036121522 10.1016/S1078-1439(01)00153-3
96. Zachos I., Konstantinopoulos P. A., Vandoros G. P., Karamouzis M. V., Papatsoris A. G., Podimatas T., Papachristodoulou A., Chrisofos M., Deliveliotis C., Papavassiliou A. G., Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy. Journal of Cancer Research and Clinical Oncology 2009 135 9 1169 1175 2-s2.0-68549141398 10.1007/s00432-009-0557-9
97. Inman B. A., Sebo T. J., Frigola X., Dong H., Bergstralh E. J., Frank I., Fradet Y., Lacombe L., Kwon E. D., PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 2007 109 8 1499 1505 2-s2.0-34247113727 10.1002/cncr.22588 (Pubitemid 46595684)
98. Honda S. I., Sakamoto Y., Fujime M., Kitagawa R., Immunohistochemical study of tumor-infiltrating lymphocytes before and after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. International Journal of Urology 1997 4 1 68 73 2-s2.0-0030890203 (Pubitemid 27129271)
99. Ardelt P. U., Kneitz B., Adam P., Reiss C., Kocot A., Fensterle J., Chen L., Pasqualini R., Arap W., Gerharz E. W., Riedmiller H., Reactive antibodies against bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder. Cancer 2010 116 3 600 609 2-s2.0-76249098429 10.1002/cncr.24770
100. Whitson J., Berry A., Carroll P., Konety B., A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. British Journal of Urology International 2009 104 3 336 339 2-s2.0-68049112265 10.1111/j.1464-410X. 2009.08375.x
101. Savic S., Zlobec I., Thalmann G. N., Engeler D., Schmauss M., Lehmann K., Mattarelli G., Eichenberger T., Dalquen P., Spieler P., Schoenegg R., Gasser T. C., Sulser T., Forster T., Zellweger T., Casella R., Bubendorf L., The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. International Journal of Cancer 2009 124 12 2899 2904 2-s2.0-65649113931 10.1002/ijc.24258
102. Mengual L., Marín-Aguilera M., Ribal M. J., Burset M., Villavicencio H., Oliver A., Alcaraz A., Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guerin therapy. European Urology 2007 52 3 752 759 2-s2.0-34547193783 10.1016/j.eururo.2007.03.001 (Pubitemid 47126159)
103. Kipp B. R., Karnes R. J., Brankley S. M., Harwood A. R., Pankratz V. S., Sebo T. J., Blute M. M., Lieber M. M., Zincke H., Halling K. C., Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. Journal of Urology 2005 173 2 401 404 2-s2.0-19944433978 10.1097/01.ju.0000149825.83180.a4
104. Saint F., Patard J. J., Irani J., Salomon L., Hoznek A., Legrand P., Debois H., Abbou C. C., Chopin D. K., Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology 2001 57 4 617 621 2-s2.0-0035321284